{"id":57522,"date":"2021-11-02T18:49:18","date_gmt":"2021-11-02T16:49:18","guid":{"rendered":"https:\/\/blog.cofb.cat\/?p=57522"},"modified":"2024-04-05T10:50:12","modified_gmt":"2024-04-05T10:50:12","slug":"actualitzacio-en-el-tractament-del-cancer-de-prostata-nova-formacio-al-cofb-adrecada-a-farmaceutics-hospitalaris-i-datencio-primaria","status":"publish","type":"post","link":"https:\/\/www.cofb.org\/es\/2021\/11\/02\/actualitzacio-en-el-tractament-del-cancer-de-prostata-nova-formacio-al-cofb-adrecada-a-farmaceutics-hospitalaris-i-datencio-primaria\/","title":{"rendered":"Actualizaci\u00f3n en el tratamiento del c\u00e1ncer de pr\u00f3stata. Nueva formaci\u00f3n en el COFB dirigida a farmac\u00e9uticos hospitalarios y de Atenci\u00f3n Primaria"},"content":{"rendered":"<p>El pasado <strong>28 de octubre<\/strong> tuvo lugar en <strong>Col\u00b7legi de Farmac\u00e8utics de Barcelona (COFB)<\/strong> la formaci\u00f3n<strong> \u201cActualizaci\u00f3n en el tratamiento del c\u00e1ncer de pr\u00f3stata. \u00bfQu\u00e9 hay de nuevo?\u201d<\/strong>, patrocinada por <a href=\"https:\/\/www.janssen.com\/es\">Janssen<\/a> y dirigida a <strong>farmac\u00e9uticos de hospitales<\/strong> y de <strong>Centros de Atenci\u00f3n Primaria<\/strong>. La actividad tuvo como ponentes al doctor <strong>Arturo Dom\u00ednguez<\/strong>, ur\u00f3logo del Hospital Universitario Parc Taul\u00ed de Sabadell; el doctor <strong>Albert Font,<\/strong> jefe de la Unidad de Urolog\u00eda del Servicio de Oncolog\u00eda M\u00e9dica del Instituto Catal\u00e1n de Oncolog\u00eda y David Conde, farmac\u00e9utico adjunto del Servicio de Farmacia del Hospital del Mar y vocal de Hospitales del COFB, que tambi\u00e9n fue el coordinador de la sesi\u00f3n. <\/p>\n\n\n\n<figure class=\"wp-block-image size-full\"><img decoding=\"async\" src=\"https:\/\/blog.cofb.cat\/wp-content\/uploads\/2021\/10\/CP59-2.png\" alt=\"\" class=\"wp-image-57635\"\/><\/figure>\n\n\n\n<p>Uno de los objetivos de la <strong>formaci\u00f3n<\/strong> consist\u00eda en poner al d\u00eda los <strong>avances del diagn\u00f3stico<\/strong>, en los <strong>tratamientos del c\u00e1ncer de pr\u00f3stata<\/strong> y las <strong>recomendaciones de las gu\u00edas<\/strong>. Por otro lado, otro de los objetivos era <strong>saber qu\u00e9 aporta la terapia hormonal<\/strong> de la nueva generaci\u00f3n y <strong>poder identificar y prevenir las interacciones medicamentosas <\/strong>y <strong>conocer el perfil de seguridad<\/strong> de estos tratamientos.<\/p>\n\n\n\n<p><div class=\"destacat-blog\"><\/p>\n\n\n\n<h1 class=\"wp-block-heading\"><strong>Nuevas terapias hormonales en el tratamiento de los c\u00e1nceres<\/strong><\/h1>\n\n\n\n<p>El <strong>c\u00e1ncer de pr\u00f3stata<\/strong> es el segundo con m\u00e1s <strong>prevalencia en el hombre<\/strong>. El incremento de las determinaciones del ant\u00edgeno prost\u00e1tico espec\u00edfico (PSA) ha favorecido su detecci\u00f3n y, por tanto, la <strong>incidencia<\/strong>. Las <strong>nuevas terapias hormonales<\/strong> en el <strong>tratamiento de algunos c\u00e1nceres<\/strong> de este tipo han demostrado que <strong>aumentan la supervivencia<\/strong> y <strong>mejoran la calidad de vida.<\/strong> <\/p>\n\n\n\n<p><\/div><\/p>\n\n\n\n<h1 class=\"wp-block-heading\"><strong>Desarrollo de la sesi\u00f3n<\/strong> <\/h1>\n\n\n\n<p>El <strong>Dr. Arturo Dom\u00ednguez<\/strong> se centr\u00f3 en las <strong>novedades en el diagn\u00f3stico y seguimiento del c\u00e1ncer de pr\u00f3stata<\/strong>, abordando las <strong>t\u00e9cnicas de imagen de nueva generaci\u00f3n<\/strong> -que aumentan el<strong>exactitud diagn\u00f3stica<\/strong>\u2013 y las <strong>recomendaciones de las gu\u00edas<\/strong>. Al comienzo de su intervenci\u00f3n, el dr. Dom\u00ednguez expuso las conclusiones de un estudio titulado <em>&quot;La valoraci\u00f3n de la esperanza de vida de los pacientes: \u00bfc\u00f3mo de precisos son los ur\u00f3logos y los onc\u00f3logos?&quot;<\/em> que resaltaba que, en algunos casos, se hab\u00eda infraestimado la expectativa de vida y, por tanto, se hab\u00eda infratratado a los pacientes, mientras que, en otras ocasiones, se hab\u00eda sobretratado a pacientes no aptos porque se hab\u00eda sobreestimado la su expectativa de vida.<\/p>\n\n\n\n<p>En este sentido, una de las <strong>conclusiones<\/strong> que resalt\u00f3 el ur\u00f3logo del Hospital Parc Taul\u00ed al final de su intervenci\u00f3n fue que las decisiones se deben<strong>individualizar <\/strong>en funci\u00f3n de la<strong> fragilidad<\/strong> y <strong>la esperanza de vida<\/strong> y no por <strong>edad biol\u00f3gica<\/strong>. <\/p>\n\n\n\n<figure class=\"wp-block-image size-large is-resized\"><img fetchpriority=\"high\" decoding=\"async\" src=\"https:\/\/blog.cofb.cat\/wp-content\/uploads\/2021\/10\/CP12-1024x585.png\" alt=\"El Dr. Arturo Dom\u00ednguez, ur\u00f2leg de l'Hospital Universitari Parc Taul\u00ed de Sabadell\" class=\"wp-image-57642\" width=\"836\" height=\"477\" title=\"El dr. Arturo Dom\u00ednguez, ur\u00f3logo del Hospital Universitario Parc Taul\u00ed de Sabadell\"\/><figcaption>El dr. Arturo Dom\u00ednguez, ur\u00f3logo del Hospital Universitario Parc Taul\u00ed de Sabadell.<\/figcaption><\/figure>\n\n\n\n<p>A continuaci\u00f3n, el<strong> Dr. Albert Font<\/strong> expuso qu\u00e9 aporta al tratamiento la <strong>terapia hormonal<\/strong> de nueva generaci\u00f3n. Al principio de su intervenci\u00f3n, hizo un repaso del<strong>evoluci\u00f3n <\/strong>del <strong>tratamiento del c\u00e1ncer de pr\u00f3stata avanzado<\/strong> en las \u00faltimas d\u00e9cadas. Si en 2000 la pregunta formulada era <em>&quot;\u00bfQu\u00e9 podemos ofrecer a los pacientes con c\u00e1ncer de pr\u00f3stata avanzado?&quot;<\/em>; en la actualidad, y teniendo en cuenta la evoluci\u00f3n del tratamiento, las preguntas que se plantean son: <em>\u201c\u00bfCu\u00e1l es el mejor tratamiento?, \u00bfEn qu\u00e9 paciente?, \u00bfEn qu\u00e9 momento debe administrarse?\u201d<\/em>. <\/p>\n\n\n\n<figure class=\"wp-block-image size-full\"><img decoding=\"async\" src=\"https:\/\/blog.cofb.cat\/wp-content\/uploads\/2021\/10\/CP20.png\" alt=\"El Dr. Font, cap de la Unitat d'Urologia del Servei d'Oncologia M\u00e8dica de l'Institut Catal\u00e0 d'Oncologia.\" class=\"wp-image-57673\" title=\"El dr. Font, jefe de la Unidad de Urolog\u00eda del Servicio de Oncolog\u00eda M\u00e9dica del Instituto Catal\u00e1n de Oncolog\u00eda.\"\/><figcaption>El dr. Font, jefe de la Unidad de Urolog\u00eda del Servicio de Oncolog\u00eda M\u00e9dica del Instituto Catal\u00e1n de Oncolog\u00eda.<\/figcaption><\/figure>\n\n\n\n<p>Entre otras cuestiones, el <strong>Dr. Fuente<\/strong> tambi\u00e9n abord\u00f3 cu\u00e1les son los <strong>factores determinantes<\/strong> para decidir la <strong>mejor opci\u00f3n de tratamiento<\/strong> en el <strong>CPHSm<\/strong> (c\u00e1ncer de pr\u00f3stata metast\u00e1sico hormonosensible). En relaci\u00f3n con la <strong>enfermedad<\/strong>, hay que tener en cuenta el volumen de esta (alto\/bajo) y el <strong>tratamiento local previo<\/strong> o bien <strong>\u201cde novo\u201d<\/strong>. En cuanto al <strong>paciente<\/strong>, hay que tener en cuenta las comorbilidades y su estado general (escala <strong>ECOG<\/strong> <em>Eastern Cooperative Oncology Group<\/em>, que <strong>mide la calidad de vida de un paciente oncol\u00f3gico<\/strong>). Y, en cuanto al <strong>tratamiento<\/strong>, hay que considerar el<strong>eficacia<\/strong> y la <strong>toxicidad<\/strong>. En definitiva, una <strong>valoraci\u00f3n<\/strong> y <strong>decisi\u00f3n multidisciplinar <\/strong>en el \u00e1mbito de los comit\u00e9s de tumores\/unidades funcionales.<\/p>\n\n\n\n<p>Por \u00faltimo,<strong> David Conde <\/strong>se focaliz\u00f3 en las <strong>interacciones medicamentosas <\/strong>y el <strong>perfil de seguridad<\/strong> de los nuevos <strong>tratamientos hormonales<\/strong>. En su intervenci\u00f3n, el <strong>vocal de Hospitales<\/strong> del COFB hizo referencia al <strong>contexto de los pacientes con c\u00e1ncer<\/strong>: pacientes <strong>polimedicados<\/strong> y susceptibles de recibir tratamientos o medicinas alternativas que no aparecen en <strong>Plan de Medicaci\u00f3n<\/strong>: hierbas, <em>OTC<\/em>, alimentos y suplementos nutricionales\u2026 Y que a menudo que no hay una <strong>rutina general<\/strong> de <strong>revisi\u00f3n de interacciones<\/strong>, aunque en la literatura existe una elevada incidencia de interacciones descritas.<\/p>\n\n\n\n<h1 class=\"wp-block-heading\"><strong>Valoraci\u00f3n de David Conde, vocal de Hospitales del COFB<\/strong><\/h1>\n\n\n\n<p>A lo largo de la sesi\u00f3n,<strong> David Conde<\/strong>, vocal de Hospitales del COFB, destac\u00f3 la <strong>importancia<\/strong> de formaciones como \u00e9sta. \u201cCre\u00edmos que era importante focalizar el tema de la presentaci\u00f3n en el <strong>c\u00e1ncer de pr\u00f3stata<\/strong> porque es <strong>muy prevalente<\/strong> y, \u00faltimamente, hemos tenido nuevas mol\u00e9culas y cada vez se va complicando algo m\u00e1s la secuencia de tratamientos\u201d, explic\u00f3.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><img decoding=\"async\" src=\"https:\/\/blog.cofb.cat\/wp-content\/uploads\/2021\/10\/CP2-1024x589.png\" alt=\"David Conde, vocal d'Hospitals del COFB, en un moment de la formaci\u00f3. \" class=\"wp-image-57625\" title=\"David Conde, vocal de Hospitales del COFB, en un momento de su formaci\u00f3n. \"\/><figcaption>David Conde, vocal de Hospitales del COFB, en un momento de su formaci\u00f3n. <\/figcaption><\/figure>\n\n\n\n<p>Y a\u00f1adi\u00f3: \u201cPor tanto, era relevante hacer un <em><strong>stop &amp; go<\/strong><\/em> y poder <strong>revisar la evidencia que tenemos hoy en d\u00eda<\/strong>, ya no s\u00f3lo respecto de las indicaciones de tratamiento sino tambi\u00e9n de <strong>nuevas t\u00e9cnicas diagn\u00f3sticas<\/strong> y, sobre todo, el<strong>impacto<\/strong> que tiene todo esto en la <strong>supervivencia de los pacientes<\/strong>\u201c.<\/p>\n\n\n\n<p class=\"has-text-align-right\"><strong>Con el patrocinio de:<\/strong><\/p>\n\n\n\n<div class=\"wp-block-image\"><figure class=\"alignright size-full is-resized\"><a href=\"https:\/\/www.janssen.com\/es\" target=\"_blank\" rel=\"noopener\"><img decoding=\"async\" src=\"https:\/\/blog.cofb.cat\/wp-content\/uploads\/2021\/10\/Janssen.jpg\" alt=\"\" class=\"wp-image-57533\" width=\"173\" height=\"87\"\/><\/a><\/figure><\/div>\n\n\n\n<p><\/p>\n\n\n\n<p><\/p>\n\n\n\n<p><\/p>\n\n\n\n<p><strong>Otras publicaciones de inter\u00e9s:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\"><li><a href=\"https:\/\/blog.cofb.cat\/ajudar-pacients-cancer-farmacia-comunitaria\/\">Ayudar a los pacientes con c\u00e1ncer desde la farmacia comunitaria (Junio 2019)<\/a><\/li><li><a href=\"https:\/\/blog.cofb.cat\/farmaceutics-de-barcelona-es-formen-per-tenir-mes-eines-en-latencio-a-pacients-amb-cancer\/\">Farmac\u00e9uticos de Barcelona se forman para tener m\u00e1s herramientas en la atenci\u00f3n a pacientes con c\u00e1ncer (Junio 2018)<\/a><\/li><li><a href=\"https:\/\/blog.cofb.cat\/noves-perspectives-al-tractament-del-cancer-de-prostata\/\">Nuevas perspectivas en el tratamiento del c\u00e1ncer de pr\u00f3stata (Mayo 2013)<\/a><\/li><\/ul>","protected":false},"excerpt":{"rendered":"<p>El passat 28 d&#8217;octubre va tenir lloc al Col\u00b7legi de Farmac\u00e8utics de Barcelona (COFB) la formaci\u00f3 &#8220;Actualitzaci\u00f3 en el tractament del c\u00e0ncer de pr\u00f2stata. Qu\u00e8 hi ha de nou?&#8221;, patrocinada per Janssen i adre\u00e7ada a farmac\u00e8utics d&#8217;hospitals i de Centres d&#8217;Atenci\u00f3 Prim\u00e0ria. L&#8217;activitat va tenir com a ponents el doctor [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":78099,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_uag_custom_page_level_css":"","site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"disabled","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"set","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[23,57],"tags":[938,723,975,18,19,1038,480,54,70,335,45,4661,724,982,983,4583,3903,4662,63,3094,484],"class_list":["post-57522","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-destacats","category-mon-collegial","tag-atencio-primaria","tag-cancer","tag-cancer-de-prostata","tag-cofb","tag-collegi-de-farmaceutics-de-barcelona","tag-farmaceutics-hospital","tag-farmacia-hospitalaria","tag-farmacs","tag-formacio","tag-medicacio","tag-medicaments","tag-millora-de-la-qualitat-de-vida","tag-oncologia","tag-pacient-amb-cancer","tag-pacient-oncologic","tag-prevalenca","tag-terapies","tag-terapies-hormonals","tag-tractament","tag-tractaments","tag-vocalia-dhospitals"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v22.4 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Actualitzaci\u00f3 en el tractament del c\u00e0ncer de pr\u00f2stata. Nova formaci\u00f3 al COFB adre\u00e7ada a farmac\u00e8utics hospitalaris i d&#039;Atenci\u00f3 Prim\u00e0ria - Col\u00b7legi de Farmac\u00e8utics de Barcelona<\/title>\n<meta name=\"description\" content=\"El passat 28 d&#039;octubre va tenir lloc al Col\u00b7legi de Farmac\u00e8utics de Barcelona (COFB) la formaci\u00f3 &quot;Actualitzaci\u00f3 en el tractament del c\u00e0ncer de pr\u00f2stata. Qu\u00e8 hi ha de nou?&quot;, adre\u00e7ada a farmac\u00e8utics d&#039;hospitals i de Centres d&#039;Atenci\u00f3 Prim\u00e0ria.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.cofb.org\/es\/2021\/11\/02\/actualitzacio-en-el-tractament-del-cancer-de-prostata-nova-formacio-al-cofb-adrecada-a-farmaceutics-hospitalaris-i-datencio-primaria\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Actualitzaci\u00f3 en el tractament del c\u00e0ncer de pr\u00f2stata. Nova formaci\u00f3 al COFB adre\u00e7ada a farmac\u00e8utics hospitalaris i d&#039;Atenci\u00f3 Prim\u00e0ria - Col\u00b7legi de Farmac\u00e8utics de Barcelona\" \/>\n<meta property=\"og:description\" content=\"El passat 28 d&#039;octubre va tenir lloc al Col\u00b7legi de Farmac\u00e8utics de Barcelona (COFB) la formaci\u00f3 &quot;Actualitzaci\u00f3 en el tractament del c\u00e0ncer de pr\u00f2stata. Qu\u00e8 hi ha de nou?&quot;, adre\u00e7ada a farmac\u00e8utics d&#039;hospitals i de Centres d&#039;Atenci\u00f3 Prim\u00e0ria.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.cofb.org\/es\/2021\/11\/02\/actualitzacio-en-el-tractament-del-cancer-de-prostata-nova-formacio-al-cofb-adrecada-a-farmaceutics-hospitalaris-i-datencio-primaria\/\" \/>\n<meta property=\"og:site_name\" content=\"Col\u00b7legi de Farmac\u00e8utics de Barcelona\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/farmaceuticsbcn\/\" \/>\n<meta property=\"article:published_time\" content=\"2021-11-02T16:49:18+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-04-05T10:50:12+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.cofb.org\/wp-content\/uploads\/2024\/04\/CP59-2.png\" \/>\n\t<meta property=\"og:image:width\" content=\"841\" \/>\n\t<meta property=\"og:image:height\" content=\"474\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"wpAdminCofbOrg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@farmaceuticsbcn\" \/>\n<meta name=\"twitter:site\" content=\"@farmaceuticsbcn\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"wpAdminCofbOrg\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.cofb.org\/ca\/2021\/11\/02\/actualitzacio-en-el-tractament-del-cancer-de-prostata-nova-formacio-al-cofb-adrecada-a-farmaceutics-hospitalaris-i-datencio-primaria\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.cofb.org\/ca\/2021\/11\/02\/actualitzacio-en-el-tractament-del-cancer-de-prostata-nova-formacio-al-cofb-adrecada-a-farmaceutics-hospitalaris-i-datencio-primaria\/\"},\"author\":{\"name\":\"wpAdminCofbOrg\",\"@id\":\"https:\/\/www.cofb.org\/ca\/#\/schema\/person\/22ed7eea88da74b0fa4d3154ad87ffcb\"},\"headline\":\"Actualitzaci\u00f3 en el tractament del c\u00e0ncer de pr\u00f2stata. Nova formaci\u00f3 al COFB adre\u00e7ada a farmac\u00e8utics hospitalaris i d&#8217;Atenci\u00f3 Prim\u00e0ria\",\"datePublished\":\"2021-11-02T16:49:18+00:00\",\"dateModified\":\"2024-04-05T10:50:12+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.cofb.org\/ca\/2021\/11\/02\/actualitzacio-en-el-tractament-del-cancer-de-prostata-nova-formacio-al-cofb-adrecada-a-farmaceutics-hospitalaris-i-datencio-primaria\/\"},\"wordCount\":1028,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/www.cofb.org\/ca\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.cofb.org\/ca\/2021\/11\/02\/actualitzacio-en-el-tractament-del-cancer-de-prostata-nova-formacio-al-cofb-adrecada-a-farmaceutics-hospitalaris-i-datencio-primaria\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.cofb.org\/wp-content\/uploads\/2024\/04\/CP59-2.png\",\"keywords\":[\"Atenci\u00f3 prim\u00e0ria\",\"c\u00e0ncer\",\"c\u00e0ncer de pr\u00f2stata\",\"COFB\",\"Col\u00b7legi de Farmac\u00e8utics de Barcelona\",\"farmac\u00e8utics hospital\",\"farm\u00e0cia hospital\u00e0ria\",\"f\u00e0rmacs\",\"Formaci\u00f3\",\"medicaci\u00f3\",\"medicaments\",\"millora de la qualitat de vida\",\"oncologia\",\"pacient amb c\u00e0ncer\",\"pacient oncol\u00f2gic\",\"prevalen\u00e7a\",\"ter\u00e0pies\",\"ter\u00e0pies hormonals\",\"tractament\",\"tractaments\",\"Vocalia d'Hospitals\"],\"articleSection\":[\"Destacats\",\"M\u00f3n col\u00b7legial\"],\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/www.cofb.org\/ca\/2021\/11\/02\/actualitzacio-en-el-tractament-del-cancer-de-prostata-nova-formacio-al-cofb-adrecada-a-farmaceutics-hospitalaris-i-datencio-primaria\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.cofb.org\/ca\/2021\/11\/02\/actualitzacio-en-el-tractament-del-cancer-de-prostata-nova-formacio-al-cofb-adrecada-a-farmaceutics-hospitalaris-i-datencio-primaria\/\",\"url\":\"https:\/\/www.cofb.org\/ca\/2021\/11\/02\/actualitzacio-en-el-tractament-del-cancer-de-prostata-nova-formacio-al-cofb-adrecada-a-farmaceutics-hospitalaris-i-datencio-primaria\/\",\"name\":\"Actualitzaci\u00f3 en el tractament del c\u00e0ncer de pr\u00f2stata. Nova formaci\u00f3 al COFB adre\u00e7ada a farmac\u00e8utics hospitalaris i d'Atenci\u00f3 Prim\u00e0ria - Col\u00b7legi de Farmac\u00e8utics de Barcelona\",\"isPartOf\":{\"@id\":\"https:\/\/www.cofb.org\/ca\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.cofb.org\/ca\/2021\/11\/02\/actualitzacio-en-el-tractament-del-cancer-de-prostata-nova-formacio-al-cofb-adrecada-a-farmaceutics-hospitalaris-i-datencio-primaria\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.cofb.org\/ca\/2021\/11\/02\/actualitzacio-en-el-tractament-del-cancer-de-prostata-nova-formacio-al-cofb-adrecada-a-farmaceutics-hospitalaris-i-datencio-primaria\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.cofb.org\/wp-content\/uploads\/2024\/04\/CP59-2.png\",\"datePublished\":\"2021-11-02T16:49:18+00:00\",\"dateModified\":\"2024-04-05T10:50:12+00:00\",\"description\":\"El passat 28 d'octubre va tenir lloc al Col\u00b7legi de Farmac\u00e8utics de Barcelona (COFB) la formaci\u00f3 \\\"Actualitzaci\u00f3 en el tractament del c\u00e0ncer de pr\u00f2stata. Qu\u00e8 hi ha de nou?\\\", adre\u00e7ada a farmac\u00e8utics d'hospitals i de Centres d'Atenci\u00f3 Prim\u00e0ria.\",\"breadcrumb\":{\"@id\":\"https:\/\/www.cofb.org\/ca\/2021\/11\/02\/actualitzacio-en-el-tractament-del-cancer-de-prostata-nova-formacio-al-cofb-adrecada-a-farmaceutics-hospitalaris-i-datencio-primaria\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.cofb.org\/ca\/2021\/11\/02\/actualitzacio-en-el-tractament-del-cancer-de-prostata-nova-formacio-al-cofb-adrecada-a-farmaceutics-hospitalaris-i-datencio-primaria\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/www.cofb.org\/ca\/2021\/11\/02\/actualitzacio-en-el-tractament-del-cancer-de-prostata-nova-formacio-al-cofb-adrecada-a-farmaceutics-hospitalaris-i-datencio-primaria\/#primaryimage\",\"url\":\"https:\/\/www.cofb.org\/wp-content\/uploads\/2024\/04\/CP59-2.png\",\"contentUrl\":\"https:\/\/www.cofb.org\/wp-content\/uploads\/2024\/04\/CP59-2.png\",\"width\":841,\"height\":474},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.cofb.org\/ca\/2021\/11\/02\/actualitzacio-en-el-tractament-del-cancer-de-prostata-nova-formacio-al-cofb-adrecada-a-farmaceutics-hospitalaris-i-datencio-primaria\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Inici\",\"item\":\"https:\/\/www.cofb.org\/ca\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Actualitzaci\u00f3 en el tractament del c\u00e0ncer de pr\u00f2stata. Nova formaci\u00f3 al COFB adre\u00e7ada a farmac\u00e8utics hospitalaris i d&#8217;Atenci\u00f3 Prim\u00e0ria\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.cofb.org\/ca\/#website\",\"url\":\"https:\/\/www.cofb.org\/ca\/\",\"name\":\"Col\u00b7legi de Farmac\u00e8utics de Barcelona\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.cofb.org\/ca\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.cofb.org\/ca\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.cofb.org\/ca\/#organization\",\"name\":\"Col\u00b7legi de Farmac\u00e8utics de Barcelona\",\"url\":\"https:\/\/www.cofb.org\/ca\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/www.cofb.org\/ca\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.cofb.org\/wp-content\/uploads\/2023\/11\/cropped-Logotip-COFB.png\",\"contentUrl\":\"https:\/\/www.cofb.org\/wp-content\/uploads\/2023\/11\/cropped-Logotip-COFB.png\",\"width\":500,\"height\":105,\"caption\":\"Col\u00b7legi de Farmac\u00e8utics de Barcelona\"},\"image\":{\"@id\":\"https:\/\/www.cofb.org\/ca\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/farmaceuticsbcn\/\",\"https:\/\/twitter.com\/farmaceuticsbcn\",\"https:\/\/www.instagram.com\/farmaceuticsbcn\/\",\"https:\/\/www.linkedin.com\/company\/farmaceuticsbcn\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.cofb.org\/ca\/#\/schema\/person\/22ed7eea88da74b0fa4d3154ad87ffcb\",\"name\":\"wpAdminCofbOrg\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/www.cofb.org\/ca\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/1721b20b3b8ca882c3b56ec6c978c594fff670e40c0718e9190eaeeb76aae7d8?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/1721b20b3b8ca882c3b56ec6c978c594fff670e40c0718e9190eaeeb76aae7d8?s=96&d=mm&r=g\",\"caption\":\"wpAdminCofbOrg\"},\"sameAs\":[\"http:\/\/192.168.64.122\/wordpress\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Actualitzaci\u00f3 en el tractament del c\u00e0ncer de pr\u00f2stata. Nova formaci\u00f3 al COFB adre\u00e7ada a farmac\u00e8utics hospitalaris i d'Atenci\u00f3 Prim\u00e0ria - Col\u00b7legi de Farmac\u00e8utics de Barcelona","description":"El passat 28 d'octubre va tenir lloc al Col\u00b7legi de Farmac\u00e8utics de Barcelona (COFB) la formaci\u00f3 \"Actualitzaci\u00f3 en el tractament del c\u00e0ncer de pr\u00f2stata. Qu\u00e8 hi ha de nou?\", adre\u00e7ada a farmac\u00e8utics d'hospitals i de Centres d'Atenci\u00f3 Prim\u00e0ria.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.cofb.org\/es\/2021\/11\/02\/actualitzacio-en-el-tractament-del-cancer-de-prostata-nova-formacio-al-cofb-adrecada-a-farmaceutics-hospitalaris-i-datencio-primaria\/","og_locale":"es_ES","og_type":"article","og_title":"Actualitzaci\u00f3 en el tractament del c\u00e0ncer de pr\u00f2stata. Nova formaci\u00f3 al COFB adre\u00e7ada a farmac\u00e8utics hospitalaris i d'Atenci\u00f3 Prim\u00e0ria - Col\u00b7legi de Farmac\u00e8utics de Barcelona","og_description":"El passat 28 d'octubre va tenir lloc al Col\u00b7legi de Farmac\u00e8utics de Barcelona (COFB) la formaci\u00f3 \"Actualitzaci\u00f3 en el tractament del c\u00e0ncer de pr\u00f2stata. Qu\u00e8 hi ha de nou?\", adre\u00e7ada a farmac\u00e8utics d'hospitals i de Centres d'Atenci\u00f3 Prim\u00e0ria.","og_url":"https:\/\/www.cofb.org\/es\/2021\/11\/02\/actualitzacio-en-el-tractament-del-cancer-de-prostata-nova-formacio-al-cofb-adrecada-a-farmaceutics-hospitalaris-i-datencio-primaria\/","og_site_name":"Col\u00b7legi de Farmac\u00e8utics de Barcelona","article_publisher":"https:\/\/www.facebook.com\/farmaceuticsbcn\/","article_published_time":"2021-11-02T16:49:18+00:00","article_modified_time":"2024-04-05T10:50:12+00:00","og_image":[{"width":841,"height":474,"url":"https:\/\/www.cofb.org\/wp-content\/uploads\/2024\/04\/CP59-2.png","type":"image\/png"}],"author":"wpAdminCofbOrg","twitter_card":"summary_large_image","twitter_creator":"@farmaceuticsbcn","twitter_site":"@farmaceuticsbcn","twitter_misc":{"Escrito por":"wpAdminCofbOrg","Tiempo de lectura":"6 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.cofb.org\/ca\/2021\/11\/02\/actualitzacio-en-el-tractament-del-cancer-de-prostata-nova-formacio-al-cofb-adrecada-a-farmaceutics-hospitalaris-i-datencio-primaria\/#article","isPartOf":{"@id":"https:\/\/www.cofb.org\/ca\/2021\/11\/02\/actualitzacio-en-el-tractament-del-cancer-de-prostata-nova-formacio-al-cofb-adrecada-a-farmaceutics-hospitalaris-i-datencio-primaria\/"},"author":{"name":"wpAdminCofbOrg","@id":"https:\/\/www.cofb.org\/ca\/#\/schema\/person\/22ed7eea88da74b0fa4d3154ad87ffcb"},"headline":"Actualitzaci\u00f3 en el tractament del c\u00e0ncer de pr\u00f2stata. Nova formaci\u00f3 al COFB adre\u00e7ada a farmac\u00e8utics hospitalaris i d&#8217;Atenci\u00f3 Prim\u00e0ria","datePublished":"2021-11-02T16:49:18+00:00","dateModified":"2024-04-05T10:50:12+00:00","mainEntityOfPage":{"@id":"https:\/\/www.cofb.org\/ca\/2021\/11\/02\/actualitzacio-en-el-tractament-del-cancer-de-prostata-nova-formacio-al-cofb-adrecada-a-farmaceutics-hospitalaris-i-datencio-primaria\/"},"wordCount":1028,"commentCount":0,"publisher":{"@id":"https:\/\/www.cofb.org\/ca\/#organization"},"image":{"@id":"https:\/\/www.cofb.org\/ca\/2021\/11\/02\/actualitzacio-en-el-tractament-del-cancer-de-prostata-nova-formacio-al-cofb-adrecada-a-farmaceutics-hospitalaris-i-datencio-primaria\/#primaryimage"},"thumbnailUrl":"https:\/\/www.cofb.org\/wp-content\/uploads\/2024\/04\/CP59-2.png","keywords":["Atenci\u00f3 prim\u00e0ria","c\u00e0ncer","c\u00e0ncer de pr\u00f2stata","COFB","Col\u00b7legi de Farmac\u00e8utics de Barcelona","farmac\u00e8utics hospital","farm\u00e0cia hospital\u00e0ria","f\u00e0rmacs","Formaci\u00f3","medicaci\u00f3","medicaments","millora de la qualitat de vida","oncologia","pacient amb c\u00e0ncer","pacient oncol\u00f2gic","prevalen\u00e7a","ter\u00e0pies","ter\u00e0pies hormonals","tractament","tractaments","Vocalia d'Hospitals"],"articleSection":["Destacats","M\u00f3n col\u00b7legial"],"inLanguage":"es","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.cofb.org\/ca\/2021\/11\/02\/actualitzacio-en-el-tractament-del-cancer-de-prostata-nova-formacio-al-cofb-adrecada-a-farmaceutics-hospitalaris-i-datencio-primaria\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.cofb.org\/ca\/2021\/11\/02\/actualitzacio-en-el-tractament-del-cancer-de-prostata-nova-formacio-al-cofb-adrecada-a-farmaceutics-hospitalaris-i-datencio-primaria\/","url":"https:\/\/www.cofb.org\/ca\/2021\/11\/02\/actualitzacio-en-el-tractament-del-cancer-de-prostata-nova-formacio-al-cofb-adrecada-a-farmaceutics-hospitalaris-i-datencio-primaria\/","name":"Actualitzaci\u00f3 en el tractament del c\u00e0ncer de pr\u00f2stata. Nova formaci\u00f3 al COFB adre\u00e7ada a farmac\u00e8utics hospitalaris i d'Atenci\u00f3 Prim\u00e0ria - Col\u00b7legi de Farmac\u00e8utics de Barcelona","isPartOf":{"@id":"https:\/\/www.cofb.org\/ca\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.cofb.org\/ca\/2021\/11\/02\/actualitzacio-en-el-tractament-del-cancer-de-prostata-nova-formacio-al-cofb-adrecada-a-farmaceutics-hospitalaris-i-datencio-primaria\/#primaryimage"},"image":{"@id":"https:\/\/www.cofb.org\/ca\/2021\/11\/02\/actualitzacio-en-el-tractament-del-cancer-de-prostata-nova-formacio-al-cofb-adrecada-a-farmaceutics-hospitalaris-i-datencio-primaria\/#primaryimage"},"thumbnailUrl":"https:\/\/www.cofb.org\/wp-content\/uploads\/2024\/04\/CP59-2.png","datePublished":"2021-11-02T16:49:18+00:00","dateModified":"2024-04-05T10:50:12+00:00","description":"El passat 28 d'octubre va tenir lloc al Col\u00b7legi de Farmac\u00e8utics de Barcelona (COFB) la formaci\u00f3 \"Actualitzaci\u00f3 en el tractament del c\u00e0ncer de pr\u00f2stata. Qu\u00e8 hi ha de nou?\", adre\u00e7ada a farmac\u00e8utics d'hospitals i de Centres d'Atenci\u00f3 Prim\u00e0ria.","breadcrumb":{"@id":"https:\/\/www.cofb.org\/ca\/2021\/11\/02\/actualitzacio-en-el-tractament-del-cancer-de-prostata-nova-formacio-al-cofb-adrecada-a-farmaceutics-hospitalaris-i-datencio-primaria\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.cofb.org\/ca\/2021\/11\/02\/actualitzacio-en-el-tractament-del-cancer-de-prostata-nova-formacio-al-cofb-adrecada-a-farmaceutics-hospitalaris-i-datencio-primaria\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/www.cofb.org\/ca\/2021\/11\/02\/actualitzacio-en-el-tractament-del-cancer-de-prostata-nova-formacio-al-cofb-adrecada-a-farmaceutics-hospitalaris-i-datencio-primaria\/#primaryimage","url":"https:\/\/www.cofb.org\/wp-content\/uploads\/2024\/04\/CP59-2.png","contentUrl":"https:\/\/www.cofb.org\/wp-content\/uploads\/2024\/04\/CP59-2.png","width":841,"height":474},{"@type":"BreadcrumbList","@id":"https:\/\/www.cofb.org\/ca\/2021\/11\/02\/actualitzacio-en-el-tractament-del-cancer-de-prostata-nova-formacio-al-cofb-adrecada-a-farmaceutics-hospitalaris-i-datencio-primaria\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Inici","item":"https:\/\/www.cofb.org\/ca\/"},{"@type":"ListItem","position":2,"name":"Actualitzaci\u00f3 en el tractament del c\u00e0ncer de pr\u00f2stata. Nova formaci\u00f3 al COFB adre\u00e7ada a farmac\u00e8utics hospitalaris i d&#8217;Atenci\u00f3 Prim\u00e0ria"}]},{"@type":"WebSite","@id":"https:\/\/www.cofb.org\/ca\/#website","url":"https:\/\/www.cofb.org\/ca\/","name":"Col\u00b7legi de Farmac\u00e8utics de Barcelona","description":"","publisher":{"@id":"https:\/\/www.cofb.org\/ca\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.cofb.org\/ca\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/www.cofb.org\/ca\/#organization","name":"Col\u00b7legi de Farmac\u00e8utics de Barcelona","url":"https:\/\/www.cofb.org\/ca\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/www.cofb.org\/ca\/#\/schema\/logo\/image\/","url":"https:\/\/www.cofb.org\/wp-content\/uploads\/2023\/11\/cropped-Logotip-COFB.png","contentUrl":"https:\/\/www.cofb.org\/wp-content\/uploads\/2023\/11\/cropped-Logotip-COFB.png","width":500,"height":105,"caption":"Col\u00b7legi de Farmac\u00e8utics de Barcelona"},"image":{"@id":"https:\/\/www.cofb.org\/ca\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/farmaceuticsbcn\/","https:\/\/twitter.com\/farmaceuticsbcn","https:\/\/www.instagram.com\/farmaceuticsbcn\/","https:\/\/www.linkedin.com\/company\/farmaceuticsbcn\/"]},{"@type":"Person","@id":"https:\/\/www.cofb.org\/ca\/#\/schema\/person\/22ed7eea88da74b0fa4d3154ad87ffcb","name":"wpAdminCofbOrg","image":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/www.cofb.org\/ca\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/1721b20b3b8ca882c3b56ec6c978c594fff670e40c0718e9190eaeeb76aae7d8?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/1721b20b3b8ca882c3b56ec6c978c594fff670e40c0718e9190eaeeb76aae7d8?s=96&d=mm&r=g","caption":"wpAdminCofbOrg"},"sameAs":["http:\/\/192.168.64.122\/wordpress"]}]}},"uagb_featured_image_src":{"full":["https:\/\/www.cofb.org\/wp-content\/uploads\/2024\/04\/CP59-2.png",841,474,false],"thumbnail":["https:\/\/www.cofb.org\/wp-content\/uploads\/2024\/04\/CP59-2-150x150.png",150,150,true],"medium":["https:\/\/www.cofb.org\/wp-content\/uploads\/2024\/04\/CP59-2-300x169.png",300,169,true],"medium_large":["https:\/\/www.cofb.org\/wp-content\/uploads\/2024\/04\/CP59-2-768x433.png",768,433,true],"large":["https:\/\/www.cofb.org\/wp-content\/uploads\/2024\/04\/CP59-2.png",841,474,false],"1536x1536":["https:\/\/www.cofb.org\/wp-content\/uploads\/2024\/04\/CP59-2.png",841,474,false],"2048x2048":["https:\/\/www.cofb.org\/wp-content\/uploads\/2024\/04\/CP59-2.png",841,474,false],"trp-custom-language-flag":["https:\/\/www.cofb.org\/wp-content\/uploads\/2024\/04\/CP59-2-18x10.png",18,10,true]},"uagb_author_info":{"display_name":"wpAdminCofbOrg","author_link":"https:\/\/www.cofb.org\/es\/author\/wpadmincofborg\/"},"uagb_comment_info":0,"uagb_excerpt":"El passat 28 d&#8217;octubre va tenir lloc al Col\u00b7legi de Farmac\u00e8utics de Barcelona (COFB) la formaci\u00f3 &#8220;Actualitzaci\u00f3 en el tractament del c\u00e0ncer de pr\u00f2stata. Qu\u00e8 hi ha de nou?&#8221;, patrocinada per Janssen i adre\u00e7ada a farmac\u00e8utics d&#8217;hospitals i de Centres d&#8217;Atenci\u00f3 Prim\u00e0ria. L&#8217;activitat va tenir com a ponents el doctor [&hellip;]","_links":{"self":[{"href":"https:\/\/www.cofb.org\/es\/wp-json\/wp\/v2\/posts\/57522","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.cofb.org\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.cofb.org\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.cofb.org\/es\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.cofb.org\/es\/wp-json\/wp\/v2\/comments?post=57522"}],"version-history":[{"count":1,"href":"https:\/\/www.cofb.org\/es\/wp-json\/wp\/v2\/posts\/57522\/revisions"}],"predecessor-version":[{"id":78100,"href":"https:\/\/www.cofb.org\/es\/wp-json\/wp\/v2\/posts\/57522\/revisions\/78100"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.cofb.org\/es\/wp-json\/wp\/v2\/media\/78099"}],"wp:attachment":[{"href":"https:\/\/www.cofb.org\/es\/wp-json\/wp\/v2\/media?parent=57522"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.cofb.org\/es\/wp-json\/wp\/v2\/categories?post=57522"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.cofb.org\/es\/wp-json\/wp\/v2\/tags?post=57522"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}